National impact of a constraining regulatory framework on pregabalin dispensations in France, 2020–2022

Bibliographic Data

ID14906602
AuthorsJulia de Ternay (0000-0003-4239-2113, Lyon 1 Université, corresponding author), Claire Meley (Hospices Civils de Lyon), Patrick Guérin, Patrick M Guérin (0000-0002-2257-5097, Nantes Université), Sébastien Meige (0009-0003-0155-0872), Nicolas Grelaud (0009-0004-9994-6900), Benjamin Rolland (0000-0002-8666-3635, Lyon 1 Université), Mathieu Chappuy (0000-0002-3176-6039, Lyon 1 Université)
Year2025
Volume135
Pages104660
Publication date2025-01-01
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueInternational Journal of Drug Policy (JOURNAL)
Journal identifiersISSN: 0955-3959 • E-ISSN: 1873-4758
PublisherElsevier BV (PUBLISHER)
DOI10.1016/j.drugpo.2024.104660
PMID39580993
OpenAlexW4404641827
LanguageEN
Citations received1
References cited38

The constraining regulation adopted in 2021 by the French health authorities significantly curtailed total pregabalin dispensing in community pharmacies. Our findings underscore the importance of regulatory measures to limit the misuse of a prescribed medication

Cohort · Counterfactual thinking · Intervention (counseling · Medical prescription · Pregabalin · Psychiatry · Medicine · Opioid Use Disorder Treatment · Pain Management and Opioid Use · Pharmaceutical Practices and Patient Outcomes · Internal Medicine · Pharmacology

Tools

Open DOIOpen Access